An Arizona woman has recently filed an Invokana ketoacidosis lawsuit against drug manufacturers Janssen, Johnson & Johnson and Tanabe Pharma. Corp. citing negligence and concealment of risk, among other claims.

Plaintiff Sheryl D. claims in her Invokana ketoacidosis lawsuit that she suffered severe and permanent personal injuries including diabetic ketoacidosis, stroke, heart attack and severe kidney damage as a “direct and proximate result” of Invokana use.

She began taking Invokana in March 2014 and continued until May 2016.

Sheryl claims that the defendants knew about the high risks of taking Invokana yet did not warn customers, conducted nationwide sales and marketing campaigns and willfully deceived both her and the medical community.

She began taking Invokana under the assumption that it was a safe and effective treatment for diabetes. However, she claims she suffered ketoacidosis as a result of taking Invokana.

In her Invokana ketoacidosis lawsuit, she claims she would have never taken the drug had the defendants properly disclosed the ketoacidosis risks.

According to the Invokana ketoacidosis lawsuit, the plaintiff has “endured pain and suffering, emotional distress, loss of enjoyment of life, and economic loss, including significant expenses for medical care and treatment which will continue in the future.”

She seeks actual, compensatory and punitive damages from the defendants.

What is Invokana and Ketoacidosis?

Invokana is a popular drug that is prescribed to control Type 2 diabetes, a serious disease affecting more than 29 million people in the U.S.

Invokana (canagliflozin) belongs to a new class of diabetes medications called sodium-glucose co-transporter 2 (SGLT2) inhibitors.

The body’s ability to produce insulin in a person with type 2 diabetes no longer works the way it should. Diabetes patients usually develop insulin resistance and the body is unable to correctly process sugar. Invokana prevents the kidneys from reabsorbing sugar and releasing it into the blood.

However, Invokana can lead to serious side effects. In May 2015 the FDA issued a warning notifying physicians and patients of the serious Invokana side effect, ketoacidosis.

Ketoacidosis occurs when the body cannot create the proper levels of insulin to metabolize fatty acids known as ketones.  Signs of ketoacidosis often develop quickly, sometimes within 24 hours or less. Some early symptoms are:

• Excessive thirst
• Frequent urination
• Nausea and vomiting
• Abdominal pain
• Weakness or fatigue
• Shortness of breath
• Fruity-scented breath
• Confusion

Treatments for ketoacidosis can include fluid therapy, insulin therapy and electrolyte therapy.

Filing an Invokana Ketoacidosis Lawsuit

Have you or a loved one experienced dangerous Invokana side effects such as ketoacidosis after taking the drug? Invokana and other type 2 diabetes medications which include canagliflozin as their active ingredient have been linked to ketoacidosis causes.

Legal help is available for those who may have developed diabetic ketoacidosis and other complications allegedly associated with Invokana or another SGLT2 inhibitor. An experienced attorney can provide you with a free, no-obligation Invokana ketoacidosis lawsuit review.

This Invokana Ketoacidosis Lawsuit is Case No. 3:16-cv-04484 in the U.S. District Court of New Jersey, Trenton Division.